Chinanews.com, Shanghai, February 24 (Reporter Chen Jing) The reporter learned on the 24th that the National Medical Products Administration (NMPA) approved Ruifu (upatinib sustained-release tablets) for the treatment of adults and 12-year-olds. Refractory, moderate-to-severe atopic dermatitis in adolescents and above should be treated.
Atopic dermatitis is a chronic, relapsing inflammatory disease characterized by repeated intense itching and scratching, resulting in cracked, scaly, and oozing skin. There are a large number of patients with atopic dermatitis in China, and related disease symptoms have brought a heavy physical, psychological and economic burden to them.
Refu (upatinib extended-release tablets) is a selective JAK inhibitor developed by AbbVie, a global biopharmaceutical company. Relevant global phase 3 registration studies included Chinese patients. Professor Xu Jinhua, the principal investigator of the global phase 3 research project in China, director of the Department of Dermatology of Huashan Hospital Affiliated to Fudan University and director of the Shanghai Institute of Dermatology, told reporters: “In the phase 3 clinical study, a small number of patients had itching on the day of medication. Relief. The new generation of upadatinib extended-release tablets, which is taken orally once a day, brings a new treatment experience to patients and a new tool for dermatologists.”
Professor Zhang Jianzhong, director of the Department of Dermatology of Peking University People’s Hospital and chairman of the 13th Chinese Medical Association Dermatology and Venereology Branch, said in an interview with reporters on the 24th: “Atopic dermatitis seriously affects the daily life of patients and reduces the quality of life of patients. , the efficacy of existing systemic drugs is still unsatisfactory. The launch of upadatinib sustained-release tablets provides more options for the treatment of patients with atopic dermatitis.”
Another principal investigator in China of the global phase 3 research project, Professor Zheng Min, chief physician of dermatology at Zhejiang University School of Medicine and member of the scientific committee of the International Federation of Skin Inflammation and Psoriasis, said that in January 2022 the US FDA Upadatinib has just been approved for the treatment of patients with moderate to severe atopic dermatitis. Upadatinib sustained-release tablets received priority review and accelerated approval in China, achieving simultaneous global approval of a new JAK inhibitor and benefiting Chinese patients simultaneously.
AbbVie’s global vice president and general manager of China, said: “AbbVie will continue to strive to improve the disease status of atopic dermatitis and other chronic immune diseases.”(End)